155 related articles for article (PubMed ID: 9266968)
1. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations.
Lorenzi MV; Castagnino P; Chen Q; Chedid M; Miki T
Oncogene; 1997 Aug; 15(7):817-26. PubMed ID: 9266968
[TBL] [Abstract][Full Text] [Related]
2. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.
Moffa AB; Tannheimer SL; Ethier SP
Mol Cancer Res; 2004 Nov; 2(11):643-52. PubMed ID: 15561780
[TBL] [Abstract][Full Text] [Related]
3. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
4. Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.
Kouhara H; Kurebayashi S; Hashimoto K; Kasayama S; Koga M; Kishimoto T; Sato B
Oncogene; 1995 Jun; 10(12):2315-22. PubMed ID: 7784079
[TBL] [Abstract][Full Text] [Related]
5. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
[TBL] [Abstract][Full Text] [Related]
6. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase.
Sabbieti MG; Marchetti L; Gabrielli MG; Menghi M; Materazzi S; Menghi G; Raisz LG; Hurley MM
Cell Tissue Res; 2005 Feb; 319(2):267-78. PubMed ID: 15654655
[TBL] [Abstract][Full Text] [Related]
8. Regulation of fibroblast growth factor 2 and fibroblast growth factor receptors by transforming growth factor beta in human osteoblastic MG-63 cells.
Sobue T; Gravely T; Hand A; Min YK; Pilbeam C; Raisz LG; Zhang X; Larocca D; Florkiewicz R; Hurley MM
J Bone Miner Res; 2002 Mar; 17(3):502-12. PubMed ID: 11874241
[TBL] [Abstract][Full Text] [Related]
9. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs.
Ueda T; Sasaki H; Kuwahara Y; Nezu M; Shibuya T; Sakamoto H; Ishii H; Yanagihara K; Mafune K; Makuuchi M; Terada M
Cancer Res; 1999 Dec; 59(24):6080-6. PubMed ID: 10626794
[TBL] [Abstract][Full Text] [Related]
10. Activation of FGF receptors by mutations in the transmembrane domain.
Li Y; Mangasarian K; Mansukhani A; Basilico C
Oncogene; 1997 Mar; 14(12):1397-406. PubMed ID: 9136983
[TBL] [Abstract][Full Text] [Related]
11. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer.
Ricol D; Cappellen D; El Marjou A; Gil-Diez-de-Medina S; Girault JM; Yoshida T; Ferry G; Tucker G; Poupon MF; Chopin D; Thiery JP; Radvanyi F
Oncogene; 1999 Dec; 18(51):7234-43. PubMed ID: 10602477
[TBL] [Abstract][Full Text] [Related]
12. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases.
Yayon A; Ma YS; Safran M; Klagsbrun M; Halaban R
Oncogene; 1997 Jun; 14(25):2999-3009. PubMed ID: 9223663
[TBL] [Abstract][Full Text] [Related]
13. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells.
Feng S; Wang F; Matsubara A; Kan M; McKeehan WL
Cancer Res; 1997 Dec; 57(23):5369-78. PubMed ID: 9393762
[TBL] [Abstract][Full Text] [Related]
15. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2.
Matsubara A; Kan M; Feng S; McKeehan WL
Cancer Res; 1998 Apr; 58(7):1509-14. PubMed ID: 9537256
[TBL] [Abstract][Full Text] [Related]
17. Sef-S, an alternative splice isoform of sef gene, inhibits NIH3T3 cell proliferation via a mitogen-activated protein kinases p42 and p44 (ERK1/2)-independent mechanism.
Rong Z; Ren Y; Cheng L; Li Z; Li Y; Sun Y; Li H; Xiong S; Chang Z
Cell Signal; 2007 Jan; 19(1):93-102. PubMed ID: 16857343
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor 2 (Fgfr2) plays an important role in eyelid and skin formation and patterning.
Li C; Guo H; Xu X; Weinberg W; Deng CX
Dev Dyn; 2001 Nov; 222(3):471-83. PubMed ID: 11747081
[TBL] [Abstract][Full Text] [Related]
19. Extracellular point mutations in FGFR2 result in elevated ERK1/2 activation and perturbation of neuronal differentiation.
Schüller AC; Ahmed Z; Ladbury JE
Biochem J; 2008 Feb; 410(1):205-11. PubMed ID: 18039182
[TBL] [Abstract][Full Text] [Related]
20. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis.
Dell'Era P; Mohammadi M; Presta M
Mol Biol Cell; 1999 Jan; 10(1):23-33. PubMed ID: 9880324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
